Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
May 28 2019 - 7:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other
diseases of the eye today announced that Vicente Anido, Jr., Ph.D.,
Chairman and Chief Executive Officer, will present at the Jefferies
2019 Healthcare Conference on Tuesday, June 4, 2019 at 2:30 p.m.
Eastern Time in New York, NY. Dr. Anido will provide an Aerie
overview and provide a business update.
The presentation will be webcast live and may be accessed by
visiting Aerie’s website at http://investors.aeriepharma.com. A
replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization
of first-in-class therapies for the treatment of patients
with open-angle glaucoma, retinal diseases and other diseases of
the eye. Aerie’s first product, Rhopressa® (netarsudil
ophthalmic solution) 0.02%, a once-daily eye drop approved by
the U.S. Food and Drug Administration (FDA) for the
reduction of elevated intraocular pressure (IOP) in patients with
open-angle glaucoma or ocular hypertension, was launched
in the United States in April 2018. In clinical
trials of Rhopressa®, the most common adverse reactions were
conjunctival hyperemia, corneal verticillata, instillation site
pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available
at www.rhopressa.com. Aerie’s second product for the reduction
of elevated IOP in patients with open-angle glaucoma or ocular
hypertension, Rocklatan® (netarsudil and latanoprost
ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose
combination of Rhopressa® and the
widely-prescribed PGA (prostaglandin analog) latanoprost,
has been approved by the FDA and was launched
in the United States in the second quarter of 2019.
In clinical trials of Rocklatan®, the most common adverse
reactions were conjunctival hyperemia, corneal verticillata,
instillation site pain, and conjunctival hemorrhage. More
information about Rocklatan®, including the product label, is
available at www.rocklatan.com. Aerie continues to focus on
global expansion and the development of additional product
candidates and technologies in ophthalmology, including for
wet age-related macular degeneration and diabetic macular
edema. More information is available
at www.aeriepharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190528005003/en/
Media: Tad Heitmann 949-526-8747;
theitmann@aeriepharma.comInvestors: Ami Bavishi 908-947-3949;
abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024